Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Infants and children are particularly vulnerable to in utero and early-life exposures. Thus, a mother's exposures before and during pregnancy could have important consequences for her child's health, including cancer development. We examined whether birth certificate-derived maternal anthropometric characteristics were associated with increased risk of subsequent childhood cancer development, accounting for established maternal and infant risk factors. Pennsylvania birth and cancer registry files were linked by the state Department of Health, yielding a virtual cohort of births and childhood cancers from 2003 through 2016. The analysis included 1,827,875 infants (13,785,309 person-years at risk), with 2,352 children diagnosed with any cancer and 747 with leukemia before age 14 years. Children born to mothers with a body mass index (weight (kg)/height (m)2) of ≥40 had a 57% (95% confidence interval: 12, 120) higher leukemia risk. Newborn size of ≥30% higher than expected was associated with 2.2-fold and 1.8-fold hazard ratios for total childhood cancer and leukemia, respectively, relative to those with expected size. Being <30% below expected size also increased the overall cancer risk (P for curvilinearity < 0.0001). Newborn size did not mediate the association between maternal obesity and childhood cancer. The results suggest a significant role of early-life exposure to maternal obesity- and fetal growth-related factors in childhood cancer development.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6670047PMC
http://dx.doi.org/10.1093/aje/kwz118DOI Listing

Publication Analysis

Top Keywords

childhood cancer
12
cancer development
12
cancer
6
risk
5
maternal obesity
4
obesity birth
4
birth size
4
size risk
4
childhood
4
risk childhood
4

Similar Publications

Background: Population pharmacokinetic models can potentially provide suggestions for an initial dose and the magnitude of dose adjustment during therapeutic drug monitoring procedures of imatinib. Several population pharmacokinetic models for imatinib have been developed over the last two decades. However, their predictive performance is still unknown when extrapolated to different populations, especially children.

View Article and Find Full Text PDF

Background: The suppressor of tumorigenesis 2 (ST2) has emerged as one of the most promising biomarkers for predicting mortality of acute graft-versus-host disease (aGvHD) when measured at the onset of symptoms, but detailed time course studies are needed to understand the potential of ST2 as a risk marker of both aGvHD and chronic graft-versus-host disease (cGvHD), potentially allowing pre-emptive adjustment of immunosuppressive treatment.

Procedure: We measured ST2 levels in 117 children undergoing standard hematopoietic stem cell transplantation (HSCT) before conditioning and at regular intervals post-HSCT.

Results: ST2 levels were significantly increased from Day +7 in patients developing aGvHD of any grade (no GvHD: 23.

View Article and Find Full Text PDF

[Evaluation of knowledge about childhood cancer among health professionals in five cities of ColombiaAvaliação do conhecimento sobre o câncer infantil entre profissionais de saúde de cinco cidades da Colômbia].

Rev Panam Salud Publica

September 2025

Grupo Área Salud Publica Instituto Nacional de Cancerología Bogotá Colombia Grupo Área Salud Publica Instituto Nacional de Cancerología. Bogotá, Colombia.

Objective: To assess primary health care professionals' knowledge regarding the timely detection of childhood cancer in five priority cities in Colombia.

Methods: Descriptive cross-sectional study with an analytical component, of 141 nursing, general medicine, family medicine, and pediatrics professionals in five of the Colombian cities with the highest rates of mortality due to this cause. A multivariate analysis was performed to predict the percentage of success obtained on each section of the test and overall.

View Article and Find Full Text PDF

Background: Phase 1 or phase 1/2 trials are a first step in pediatric cancer drug development. Currently, there is a paucity of information regarding contemporary outcomes for pediatric patients enrolled in these trials. We describe characteristics and outcomes of patients enrolled in pediatric phase 1 clinical trials over a 9-year period at a single institution.

View Article and Find Full Text PDF

Background: Relapsed or refractory cases of pediatric acute myeloid leukemia (AML) have poor outcomes despite advancements in chemotherapy and hematopoietic stem cell transplantation (HSCT). While a second HSCT is often a salvage option, its outcomes vary widely, and prognostic factors remain unclear.

Objectives: This study aimed to evaluate outcomes and identify prognostic factors in pediatric patients with AML who underwent multiple HSCTs.

View Article and Find Full Text PDF